en.Wedoany.com Reported - Samsung Bioepis Co., Ltd. and ATLATL Innovation Center recently announced the signing of a Memorandum of Understanding on an open innovation program, aimed at driving innovation in the early-stage biotechnology sector across the Asia-Pacific region.

Through this collaboration, Samsung Bioepis seeks to leverage ATLATL's R&D network and expertise in the Asia-Pacific biotech field to identify and support promising early-stage biotech companies and breakthrough technologies.

"External innovation is becoming increasingly important in drug development—not only to identify and nurture promising early-stage technologies and companies, but also to cultivate a broader innovation ecosystem," said Min Jeong Seo, Vice President and Head of the Open Innovation Team at Samsung Bioepis. "By leveraging ATLATL's extensive network and ecosystem as one of the largest biotech incubation hubs in the Asia-Pacific, we believe this strategic partnership will help accelerate the translation of promising science into meaningful medicines for patients."

"ATLATL connects early-stage science with the infrastructure and expertise needed for practical translation," said Dr. PC Zhu, Founder and CEO of ATLATL. "Through our integrated R&D ecosystem in the Asia-Pacific and in collaboration with Samsung Bioepis, we aim to accelerate the development of high-potential technologies and bring impactful therapies to patients more efficiently."

As part of the collaboration, Samsung Bioepis plans to launch the "Innovation Award," an open innovation program in partnership with ATLATL. Through this initiative, selected early-stage biotech companies will have the opportunity to reside at ATLATL's incubation centers, utilizing its infrastructure and expertise to accelerate their growth.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com